阿根廷碳青霉烯耐药革兰阴性杆菌血流感染的前瞻性多中心队列研究
该研究为阿根廷前瞻性多中心观察性队列,纳入2020年7月至2022年3月466例碳青霉烯耐药革兰阴性杆菌血流感染住院患者,30天死亡率为52%。在肺炎克雷伯菌血流感染患者中,倾向评分调整后分析显示INCREMENT-CPE评分≥8分与30天死亡率升高相关,而含头孢他啶-阿维巴坦(单用或联用氨曲南)方案与30天死亡率降低相关。
要点
- 碳青霉烯耐药革兰阴性杆菌血流感染30天死亡率达52%。
- 肺炎克雷伯菌血流感染中,INCREMENT-CPE评分≥8分与30天死亡率升高相关(OR 3.48)。
核心结论
- 在阿根廷,碳青霉烯耐药革兰阴性杆菌血流感染与高死亡率相关。
- 在碳青霉烯耐药肺炎克雷伯菌血流感染患者中,使用头孢他啶-阿维巴坦单用或联用氨曲南与死亡率降低相关。
研究设计与样本
- 前瞻性观察性多中心研究,纳入2020年7月至2022年3月阿根廷连续住院的年龄≥18岁、血培养碳青霉烯耐药革兰阴性杆菌阳性的指示患者。
- 共纳入466例碳青霉烯耐药革兰阴性杆菌血流感染患者,平均年龄56.7岁(SD±16),75%位于重症监护病房。
- 在肺炎克雷伯菌血流感染患者中,采用倾向评分调整的logistic回归分析与30天死亡率相关的变量。
主要发现
- 最常见病原体为肺炎克雷伯菌(53%)和鲍曼不动杆菌(25%)。
- 肠杆菌目细菌中,耐药机制包括KPC 50%、金属β-内酰胺酶碳青霉烯酶48%、OXA碳青霉烯酶6%、碳青霉烯酶组合5%。
- 总体30天死亡率为52%。
- 在肺炎克雷伯菌血流感染患者中,倾向评分调整的多因素分析显示INCREMENT-CPE评分≥8分与30天死亡率升高相关(OR 3.48;95%CI 1.53-7.93)。
关键数值与推荐
- INCREMENT-CPE死亡评分中位数为10分(IQR 6-12)。
- 肺炎克雷伯菌血流感染中,INCREMENT-CPE评分≥8分与30天死亡率升高相关(OR 3.48;95%CI 1.53-7.93)。
临床怎么用
- 在碳青霉烯耐药革兰阴性杆菌血流感染中,可参考INCREMENT-CPE评分评估死亡风险。
- 对碳青霉烯耐药肺炎克雷伯菌血流感染,含头孢他啶-阿维巴坦单用或联用氨曲南的方案与死亡率降低相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bloodstream infections (BSIs) caused by carbapenem-resistant gram-negative bacilli (CR-GNB) are difficult-to-treat infections associated with high mortality. Outcomes of BSI due to CR-GNB may vary in different countries. METHODS: Prospective observational, multicenter study, including consecutive hospitalized index patients aged ≥18 years, with a positive blood culture for CR-GNB, between July 2020 and March 2022 in Argentina. Among patients with Klebsiella pneumoniae BSIs, logistic regressions adjusted by propensity score (PS) were used to identify variables associated with 30-day mortality. RESULTS: Overall, 466 patients with CR-GNB BSIs were included. The mean age was 56.7 (SD ±16) years and most patients (75%) were in critical care units. The median INCREMENT-CPE mortality score was 10 (IQR, 6-12). Most common micro-organisms were K pneumoniae (53%) and Acinetobacter baumannii (25%). Among Enterobacterales, resistance mechanisms included K pneumoniae carbapenemase (KPC) in 50%, metallo-beta-lactamase carbapenemase (MBL) in 48%, OXA carbapenemase in 6%, and a combination of carbapenemases in 5% of patients. Overall, 30-day mortality was 52%. Among patients with BSI due to K pneumoniae, the PS-adjusted multivariate analysis showed that an INCREMENT-CPE score ≥8 points (odds ratio [OR], 3.48; 95% CI, 1.53, 7.93) was associated with increased 30-day mortality. In contrast, the use of regimens including ceftazidime-avibactam alone or in combination with aztreonam was associated with decreased 30-day mortality (OR, .20; 95% CI, .09, .47). CONCLUSIONS: BSIs due to CR-GNB are associated with high mortality rates in Argentina. Among patients with CR-K pneumoniae bacteremia the use of ceftazidime-avibactam alone or in combination with aztreonam was associated with a reduction in mortality.
引用
- Balbuena JP, Cordova E, Mykietiuk A, et al. Carbapenem-Resistant Gram-Negative Bacilli Bacteremia in Argentina (EMBARCAR): Findings From a Prospective, Multicenter Cohort Study. Clin Infect Dis. 2025. PMID: 40393137. doi:10.1093/cid/ciaf259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。